From Zero to Market in Asia,
Fast-track registration, early access & end-to-end commercialization across Greater China, Southeast Asia & key global markets
ACA Pharma helps innovative medicines and medical devices reach patients across Asia faster, with less time, cost and complexity. We specialize in accelerated market-entry pathways, including Macau’s 30–90 day fast-track route for medicines and Hong Kong-based device pathways that can unlock access to the Greater Bay Area and Hainan pilot zones in as little as three months.
Through our Asian Patient Access Program (APAP), we also support group NPP purchasing across our hospital network for pre-approval access. From regulatory strategy and registration to distribution, hospital access, and in-market execution, we manage the process end-to-end so our partners can focus on product, supply and scale.
Recent News
Who We Are
ACA Pharma is a U.S.-headquartered, licensed partner built to help innovative medicines and medical devices reach patients faster across Asia. We're a single, easy party to contract with and operate through established, licensed entities with teams, warehouses and on-the-ground personnel across Macau, Hong Kong, Singapore, and Mainland China, with on-the-ground sales coverage reaching every province.
Speed to Market
- FDA, EMA, MHRA referenced registrations
- Medicines: 30-90 days Macau approval
- Devices: ~3 month Hong Kong approval
- Bridge into Mainland China pilot zones
- RWE supports accelerated national approval
End-to-End Execution
- Registration through launch
- Import permits & logistics
- Expert, KOL-driven promotion
- Key Mainland SOE partnerships
- Commercial scale-up after entry
Asset-Light Model
- No upfront build-out
- We fund local execution
- Partners supply product
- Partners retain all IP
- Our costs recovered post-launch
A Smarter Way to Enter Underserved Markets
ACA Pharma helps innovative medicines reach underserved, high-growth markets with greater speed, lower risk, and less complexity. Many companies assume these markets require years of local trials, significant investment, and heavy in-country infrastructure. Often, they do not. We provide an end-to-end, capital-efficient model that manages regulatory, market access, distribution, and local execution—helping partners expand access in months, not years. We manage the local pathway end-to-end, allowing our partners to focus on what they do best: ensuring product supply while we handle the rest.
SEE OUR PIPELINE →